Approximately 43,000 people in the U.S. are diagnosed with tumors of the mouth, pharynx and larynx each year. The main risk factor is smoking, but a recent rise in cases has been linked to human papillomavirus. Most cases are not diagnosed until the cancer has reached an advanced stage.
“There’s a lot out there about breast, prostate and brain cancer, but people are not so aware about oral cancer and its devastating consequences,” said Laura Marcu, a professor of biomedical engineering at UC Davis. “People don’t think to look for it, and there isn’t any routine screening.”
Marcu’s laboratory collaborated with Dr. Gregory Farwell’s group in the Department of Otolaryngology at the UC Davis Cancer Center to develop the fiber-optic probe.
The probe stimulates molecules in the patient’s tissues with a laser. Some of these molecules naturally respond by re-emitting fluorescent light. The device rapidly detects and analyzes this light using a process called “time-resolved fluorescence spectroscopy” (TR-LIFS), which provides information about the types of molecules present.
During surgery, blood can distort the intensity of the fluorescence signal but not its duration. By using sensitive measurements of the change in fluorescence over time, surgeons can see the tumor margins even as they are cutting the tissue.
Based on encouraging results in animal tests, Marcu and Farwell’s team recruited nine human volunteers from among patients who arrived at the UC Davis Medical Center for surgical therapy of the mouth, throat and larynx. They compared readings from spectroscopy with biopsy samples from the same locations and found that the probe could accurately diagnose the cancer in the surgical environment.
The probe is similar to one that Marcu has already developed for use with brain tumors. In clinical trials, surgeons have used her technology to delineate the margins of tumors during surgery.
Details of the human oral cancer study will be published in an upcoming issue of the journal Otolaryngology — Head and Neck Surgery. The pilot study in patients was supported in part by the Cancer Center and the Clinical and Translational Science Center at the UC Davis School of Medicine and the UC Davis Center for Biophotonics Science and Technology.
Designated by the National Cancer Institute, UC Davis Cancer Center is leading the way in identifying the molecular pathogenesis of carcinoma of the prostate, enhancing therapeutic response and identifying chemopreventions. For more information, visit the Cancer Center Web site.